SCHEMBL2936754

SCHEMBL2936754

Cc1ccc(C(=O)NC[C@H](NC(=O)c2cnccn2)C(=O)N[C@@H](CC(C)C)B(O)O)cc1

nearest known ligand 0.69

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LONP1 P36776 16/20 0.69
PSMB5 P28074 12/20 0.67
PSMB11 A5LHX3 9/20 0.65
PSMA7 O14818 9/20 0.65
PSMB1 P20618 9/20 0.65
PSMA1 P25786 9/20 0.65
PSMA2 P25787 9/20 0.65
PSMA3 P25788 9/20 0.65
PSMA4 P25789 9/20 0.65
PSMB8 P28062 9/20 0.65
PSMB9 P28065 9/20 0.65
PSMA5 P28066 9/20 0.65
PSMB4 P28070 9/20 0.65
PSMB6 P28072 9/20 0.65
PSMB10 P40306 9/20 0.65
PSMB3 P49720 9/20 0.65
PSMB2 P49721 9/20 0.65
PSMA6 P60900 9/20 0.65
PSMA8 Q8TAA3 9/20 0.65
PSMB7 Q99436 9/20 0.65

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2926138 0.88 PSMB5 (0.67) LONP1PSMB5PSMB11PSMA7PSMB1
SCHEMBL8257202 0.88 PSMB5 (0.67) LONP1PSMB5PSMB11PSMA7PSMB1
SCHEMBL2926124 0.86 PSMB5 (0.54) LONP1PSMB5PSMB11PSMA7PSMB1
SCHEMBL13524729 0.86 PSMB5 (0.84) LONP1PSMB5PSMB11PSMA7PSMB1
SCHEMBL3143815 0.85 LONP1 (0.66) LONP1PSMB5PSMB11PSMA7PSMB1
SCHEMBL19382087 0.85 LONP1 (0.66) LONP1PSMB5PSMB11PSMA7PSMB1
SCHEMBL3143828 0.85 LONP1 (0.66) LONP1PSMB5PSMB11PSMA7PSMB1
SCHEMBL2929343 0.85 PSMB5 (0.55) LONP1PSMB5PSMB11PSMA7PSMB1
SCHEMBL3169902 0.84 LONP1 (0.66) LONP1PSMB5PSMB11PSMA7PSMB1
SCHEMBL8259978 0.84 PSMB5 (0.59) LONP1PSMB5PSMB11PSMA7PSMB1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1846424-B1 PROTEASOME INHIBITORS AND METHODS OF USING THE SAME CEPHALON INC (US) 2010-01-27 EP claimed
US-8283367-B2 Proteasome inhibitors and methods of using the same CEPHALON, INC. (US) 2012-10-09 US disclosed
US-8283367-B2 Proteasome inhibitors and methods of using the same CEPHALON, INC. (US) 2012-10-09 US disclosed
US-20090075936-A1 Proteasome inhibitors and methods of using the same CEPHALON, INC. (US) 2009-03-19 US disclosed
US-20090075936-A1 Proteasome inhibitors and methods of using the same CEPHALON, INC. (US) 2009-03-19 US disclosed
US-7468383-B2 Proteasome inhibitors and methods of using the same CEPHALON, INC. (US) 2008-12-23 US disclosed
US-7468383-B2 Proteasome inhibitors and methods of using the same CEPHALON, INC. (US) 2008-12-23 US disclosed
WO-2006086600-A1 PROTEASOME INHIBITORS AND METHODS OF USING THE SAME CEPHALON, INC. (US) 2006-08-17 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090075936-A1 Proteasome inhibitors and methods of using the same PSMB11, PSMB5, PSMB6 LONP1 277/4885PSMB5 2/4885PSMB11 1/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.